Saturday 17 October 2026
Export PMCB’s income statement to Excel — free account
Nuvilex Inc.
PMCB Healthcare Biotechnology
In the quarter to July 2026, EPS grew 56.1% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.34
0.02
−5.56%
Follow PMCB
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(28.07%) | (24.38%) | (54.48%) | (58.04%) | |
| (19.88%) | (19.17%) | (45.54%) | (50.43%) | ||
ROIC |
(13.46%) | (19.15%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(51.50%) | (50.24%) | (63.42%) | (68.30%) | |
Average Days of Receivables |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.67) | (0.52) | (0.61) | (0.37) | |
Free Cash Flow |
(4.52) | (4.80) | (5.15) | (3.94) | |
| Other line items | |||||
Cash ROIC |
(8.90%) | (8.19%) | (7.32%) | (6.79%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Operating CF/Net income |
0.41 | 0.50 | 0.22 | 0.19 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.67) | (0.52) | (0.61) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Oct 2026